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Panton-Valentine
Leukocidin–
producing
Staphylococcus
aureus 
To the Editor: Panton-Valentine
leukocidin (PVL) is a cytotoxin pro-
duced by Staphylococcus aureus that
causes leukocyte destruction and tis-
sue necrosis (1). Although produced
by <5% of S. aureus strains, the toxin
is detected in large percentages of iso-
lates that cause necrotic skin lesions
and severe necrotizing pneumonia (2).
Although commonly associated with
community-acquired methicillin-
resistant  S. aureus (CA-MRSA) (3),
several outbreaks due to methicillin-
susceptible  S. aureus (MSSA) have
also been reported (4–6). We describe
an outbreak of cutaneous infections
caused by PVL-producing MSSA that
affected 6 of 11 members of 2 related
families.
During a period of 6 months, a
cluster of S. aureus skin and soft tis-
sue infections occurred in 2 families
in Jerusalem, Israel, that were related
through the mothers, who are sisters.
The event started with the 4-year-old
boy of family A, who had 5 episodes
of skin infections, including 2
episodes of perianal abscesses that
required drainage and hospitalization.
Culture of pus grew MSSA that was
resistant to erythromycin and clin-
damycin. Subsequently, recurrent
abscesses and cellulitis developed in
the boy’s father’s legs, and his mother
had severe periorbital cellulitis that
required hospitalization and surgical
drainage. Approximately 1 month
later, a 9-year-old boy in family B had
severe cellulitis and abscess around
his knee that required hospitalization
and surgical drainage. Subsequently,
infections developed in 2 more chil-
dren in family B: 1 had a finger pulp-
space infection and the other cellulitis
of the lower abdomen. All pus cul-
tures grew S. aureus with identical
susceptibility patterns. The cases are
summarized in the Table.
Following these events, the fami-
lies consulted the infectious diseases
clinic at the Hadassah-Hebrew
University Medical Center in
Jerusalem. Since the clinical isolates
were not available, nasal cultures
were obtained from all family mem-
bers. S. aureus was isolated from all
the affected members of family A and
from the parents and the 2 boys in
family B. All 7 isolates were subject-
ed to pulsed-field gel electrophoresis
(PFGE) after digestion with SmaI. All
except 1 had identical band patterns
and the same antimicrobial drug sus-
ceptibilities as the clinical isolates.
The presence of PVL genes was
examined by PCR as previously
described (2) and was detected only in
the isolates with identical PFGE pat-
terns. The families were advised to
apply mupirocin nasal ointment twice
a day for 5 days and to bathe with 4%
chlorhexidine scrub for 1 week (7). At
7 months of follow-up, no new cases
of skin infection had occurred in
either family. An epidemiologic
investigation was undertaken by the
local department of health to deter-
mine if 3 kindergartens and 2 schools
attended by the 7 children had an
increased incidence of staphylococcal
skin disease. No evidence of unusual
disease was found.
We describe here the first con-
firmed cases of PVL-producing S.
aureus infections in Israel. Maier et al
(8) recently described 2 cases of simi-
lar infections that occurred in German
tourists after visiting the Dead Sea
area, but since these infections were
caused by MRSA, it is probable that
the isolates were genetically distinct
from the strain described here. In addi-
tion, to the best of our knowledge this
is the first description of transmission
of PVL-producing MSSA between
related families. Previous reports
described community-related out-
breaks that occurred within families
(6,8,9), between schoolmates (4), and
between football team players (10).
The exact route of transmission was
not identified in some of these cases
but it was presumed to have been close
contact leading to skin (10) or nasal
(4) colonization and subsequent active
infection. In our report, the PVL-pro-
ducing S. aureus clone was detected inLETTERS
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nasal cultures in 6 of the 11 members
of the 2 families. In this niche, it was
able to persist and cause a series of
infections in a relatively large number
of family members. Even though the
S. aureus isolated from active lesions
were not available for testing, the
recovery of identical PVL-positive
organisms from nasal cultures strong-
ly suggests the presence of a patho-
genic clone that probably caused the
recurrent infections in the 6 affected
family members. Our investigation
highlights the high transmissibility of
this PVL-producing S. aureus clone,
its high attack rate, and its virulence.
The intervention in this outbreak
might have prevented not only subse-
quent recurrences of cutaneous infec-
tions but also further spread of this
clone and the manifestation of even
more serious infections such as necro-
tizing pneumonia. Increasing aware-
ness among community-based health-
care providers of PVL-producing S.
aureus infections is important to facil-
itate rapid and adequate response in
similar clinical events in the future.
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Chikungunya Fever,
Hong Kong 
To the Editor: Chikungunya virus
disease, caused by a mosquitoborne
alphavirus, is endemic to Africa and
Southeast Asia. It typically causes an
acute febrile illness, with joint pain
and a skin rash. Chronic arthropathy
may develop (1,2). No treatment or
vaccine is available, and relatively lit-
tle research has been conducted into
its pathogenesis, compared with that
of other arboviruses, such as dengue.
Recent reports have described a mas-
sive outbreak of chikungunya disease
occurring on islands in the Indian
Ocean, off the east coast of Africa (1).
Reemergence of chikungunya has also
been reported from Indonesia (2).
During March 2006, a 66-year-old
Chinese man from Hong Kong visited
Mauritius where he was bitten by
mosquitoes 2 days before returning to
Hong Kong. On the return trip, he
experienced fever (39°C), severe fin-
ger joint and muscle pains, mild
headache, and a skin rash, and he
sought treatment at the Prince of
Wales Hospital (PWH) Infectious
Diseases Clinic on the second day of
his illness. Physical examination
showed a generalized erythematous
rash over the trunk and limbs and
petechiae over the lower limbs. Mild
finger joint stiffness was observed,
but no joint swelling. No lym-
phadenopathy or eschar was detected.
Level of C-reactive protein was ele-
vated at 10.4 mg/L. Results of screens
for malaria and dengue were negative.
Results of other routine assessments
were unremarkable. His symptoms
subsided gradually within a week.
Serum specimens taken on days 2
and 6 were positive for chikungunya
virus RNA by in-house reverse tran-
scription (RT)-PCR at the Public
Health Laboratory Service (PHLS)
(targeting the nonstructural protein-1
[NSP-1] gene) and PWH laboratory
(targeting both NSP-1 and the enve-
lope glycoprotein [E1] gene). An